These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23914988)

  • 1. Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).
    McAllister-Williams RH; Smith E; Anderson IM; Barnes J; Gallagher P; Grunze HC; Haddad PM; House AO; Hughes T; Lloyd AJ; McColl EM; Pearce SH; Siddiqi N; Sinha B; Speed C; Steen IN; Wainright J; Watson S; Winter FH; Ferrier IN
    BMC Psychiatry; 2013 Aug; 13():205. PubMed ID: 23914988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
    McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
    Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metyrapone in treatment-resistant depression.
    Sigalas PD; Garg H; Watson S; McAllister-Williams RH; Ferrier IN
    Ther Adv Psychopharmacol; 2012 Aug; 2(4):139-49. PubMed ID: 23983967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
    Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
    BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression.
    Au-Yeung SK; Griffiths J; Roberts S; Edwards C; Yu LM; Bogacz R; Rendell J; Attenburrow MJ; Watson S; Chan F; Cipriani A; Cleare A; Harmer CJ; Kessler D; Evans J; Lewis G; Singh I; Simon J; Harrison PJ; Cowen P; Shanyinde M; Geddes J; Browning M
    Evid Based Ment Health; 2022 May; 25(2):77-83. PubMed ID: 34810175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study).
    Marwood L; Taylor R; Goldsmith K; Romeo R; Holland R; Pickles A; Hutchinson J; Dietch D; Cipriani A; Nair R; Attenburrow MJ; Young AH; Geddes J; McAllister-Williams RH; Cleare AJ
    BMC Psychiatry; 2017 Jun; 17(1):231. PubMed ID: 28651526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Weston J; Singh J; Marson AG
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol.
    Maji S; Mohapatra D; Jena M; Srinivasan A; Maiti R
    BMJ Open; 2024 Apr; 14(4):e080500. PubMed ID: 38688675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
    Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
    Husain MI; Chaudhry IB; Rahman RR; Hamirani MM; Qurashi I; Khoso AB; Deakin JF; Husain N; Young AH
    Trials; 2015 Sep; 16():410. PubMed ID: 26374703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial.
    Sharp DJ; Chew-Graham C; Tylee A; Lewis G; Howard L; Anderson I; Abel K; Turner KM; Hollinghurst SP; Tallon D; McCarthy A; Peters TJ
    Health Technol Assess; 2010 Sep; 14(43):iii-iv, ix-xi, 1-153. PubMed ID: 20860888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient decision aid for antidepressant use in pregnancy: study protocol for a randomized controlled trial.
    Vigod S; Hussain-Shamsy N; Grigoriadis S; Howard LM; Metcalfe K; Oberlander TF; Schram C; Stewart DE; Taylor VH; Dennis CL
    Trials; 2016 Feb; 17(1):110. PubMed ID: 26923796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.